IP Library › Granted Patent US 11,771,447
Granted Patent B2
US 11,771,447 · App. 17/127,952 · Granted Oct 3, 2023

Method of treatment with low energy extracorporeal shockwaves

Inventors: Avner Spector (Savyon, IL); Tamar Shultz More (Jerusalem, IL)
A61B17/22004A61H23/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,771,447
App. No.
17/127,952
Granted
Oct 3, 2023
Kind
B2
Abstract

A method of treatment of the human or animal body with noninvasive low energy extracorporeal shockwaves and in particular, to such a method that is utilized for controlling a cascade of biomolecular activity involving a plurality of biomolecular factors, provided to improve function of the treatment portion of the human or animal body.

Claims (10)

1. A method for preventing an onset of formation of renal fibrosis in a human or animal body for individuals suffering from cancer and as part of a cancer treatment protocol, the method comprising applying a low energy shockwave treatment protocol over a treatment area of at least a kidney of the human or animal body prior to applying a cancer treatment protocol selected from chemotherapy, biological therapy, cell therapy, or stem cell therapy, and wherein said treatment area having or expected to have acute tissue trauma,

a) the low energy shockwave treatment protocol having shockwave parameters including: an energy density from 0.02 and up to 0.2 milliJoules per millimeter squared (mJ/mm2), at a frequency of 2 Hertz (Hz);

b) wherein the low energy shockwave treatment protocol applies a number of low energy shockwaves, wherein the number of applied shockwaves is up to 5000 shockwaves, over at least a portion of the treatment area, and wherein the low energy shockwaves are delivered to the treatment area triggering a cascade of bio-molecular activity involving at least one bio-molecular factor selected from the group consisting of: Transforming Growth Factor beta (TGFbeta); Tissue Inhibitor of MetalloProteinases inhibitor1 (TIMP-1), Focal Adhesion Kinase (FAK), Stem Cell Factor (SCF), Hepatocyte Growth Factor (HGF), the cascade of bio-molecular activity operative to prevent or alleviate fibrosis in and around the treatment area wherein at least one of TGFbeta or TIMP-1 is reduced in expression or wherein of at least one of SCF, HFG or FAK is increased in expression; and

c) wherein said low energy shockwave treatment protocol is initiated within either a 48 hour window or at least one week prior to the cancer treatment protocol.

2. The method of claim 1 wherein said treatment area is divided into a plurality of small treatment zones, wherein each treatment zone is provided with at least 100 shockwaves and up to 500 shockwaves.

3. The method of claim 1 wherein said low energy shockwave treatment protocol is provided in three week treatment phases wherein each week includes up to four treatment sessions.

4. The method of claim 1 wherein said low energy shockwave treatment is provided over a span of up to 9 weeks.

5. The method of claim 4 wherein the low energy shockwave treatment protocol includes up to four active treatment sessions per week.

6. The method of claim 5 wherein the low energy shockwave treatment protocol is configured according the number of active treatment sessions or the number of applied low energy shockwaves so as to cause an increased expression of Focal Adhesion Kinase (FAK) in and around said treatment area; and wherein said increased expression of FAK is proportional to the selected number of the active treatment sessions or the number of applied low energy shockwaves.

7. The method of claim 6 wherein the number of low energy shockwaves delivered in each session is gradually decreasing.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2022
From: SPECTOR, AVNER, MR; SHULTZ MORE, TAMAR, DR
To: CURESPEC LTD.
Reel/Frame 061700/0087 →
Continuity (3)
Continuation 14938494 · Nov 11, 2015
Continuation In Part 13359538 · Jan 27, 2012
Related Publication 20210153885A1 · May 27, 2021